Genmab, a bioscience company heavily invested in antibody therapeutics, shows substantial growth, with Wells Fargo initiating coverage with an overweight rating. Furthermore, the company's recent Share
Buy-back program and
analyst attention could have a substantial impact on the investment case. There's anticipation of a price spike in the company's
stock as well from the options market. The company has taken significant steps, including updating its articles of association, expanding capital, warrant authorizations, and granting restricted stock units and warrants to employees. Analysts upgraded the stock to
Strong Buy thanks to the company's own proprietary medicine sales driving a 19% revenue growth to $3.7B by 2025.
Guggenheim however cut Genmab's stock price citing weak guidance.
AbbVie and Genmab have secured FDA approval for Epkinly for treating second-line follicular lymphoma, a promising development. Genmab recently completed a tender offer for outstanding shares of
Merus N.V., and its $2.5 billion Merus deal financing could impact investors positively. However, there has been a fall in stock after discontinuing
acasunlimab development and missing a key endpoint in a phase 3 epcoritamab trial.
Genmab Stocks News Analytics from Tue, 22 Jul 2025 07:00:00 GMT to Fri, 06 Mar 2026 06:16:30 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 3
